A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Gaucher Disease, Type 1 Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00430625
• Other study ID #: TKT032
• Status: Completed
• Phase: Phase 3
• Start date: February 15, 2007
• Est. completion date: April 1, 2009

Study information

• Verified date: June 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the efficacy of every other week dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of 45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.

Description:

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the Central Nervous System (CNS). Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. Velaglucerase alfa contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the efficacy, safety and pharmacokinetics of GA-GCB in men, women, and children with Type 1 Gaucher disease. Each patients duration of treatment was 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: April 1, 2009
• Est. primary completion date: April 1, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Patient has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and is willing and able to provide written informed consent prior to initiating any study-related procedures
• Patient is at least 2 years of age
• Patient has Gaucher disease-related anemia and
• Patient has at least moderate splenomegaly or
• Patient has Gaucher disease-related thrombocytopenia or
• Patient has a readily palpable enlarged liver
• Patient has not received treatment for Gaucher disease within 30 months prior to study entry
• Female patients of child-bearing potential agree to use a medically acceptable method of contraception. Male patients must agree to use a medically acceptable method of birth control.
• Patient must be sufficiently cooperative to participate in the study as judged by the Investigator. Exclusion Criteria:

Includes:

• Patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease
• Patient is antibody-positive to imiglucerase during screening or has experienced an anaphylactic reaction to imiglucerase
• Patient has received treatment with any investigational drug or device within the 30 days prior to study entry
• Patient is Human immunodeficiency virus (HIV) positive
• Patient is hepatitis positive
• Patient presents with iron, folic acid and/or vitamin B12 deficiency sustained anemia during screening
• Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study
• Patient has a significant comorbidity(ies)that might affect study data or confound the study results
• Patient is a pregnant and/or lactating female
• Patient is unable to comply with the protocol or is unlikely to complete the study, as determined by the Investigator

Related Conditions & MeSH terms

• Gaucher Disease
• Gaucher Disease, Type 1

Intervention

Biological:
• VPRIV ®,
Intravenous (IV) infusion, every other week via intravenous infusion for 12 months

Locations

Country	Name	City	State
Argentina	Hipolito Yrigoyen	Buenos Aires
Israel	Shaare Zedek Medical Center	Jerusalem
Paraguay	Sociedad Espanola de Socorros Mutuos	Asuncion
Russian Federation	National Research Center for Haematology	Moscow
Tunisia	La Rabta Hospital	Tunis

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Countries where clinical trial is conducted

Argentina,  Israel,  Paraguay,  Russian Federation,  Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.	Efficacy endpoint	Week 53
Secondary	Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group		Week 53
Secondary	Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group.	intent to treat (ITT) Population	Week 53
Secondary	Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)	Liver Volume has been normalized for percentage of body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cc]/Body weight [kg])*100	Week 51
Secondary	Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI))	12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population. Spleen Volume has been normalized for percent of body weight for each treatment arm. Spleen size relative to body weight = (Spleen volume [cc]/Body weight [kg])*100	Week 51
Secondary	Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group	Percent Change from Baseline to Weeks 53 by Randomized velaglucerase alfa Treatment Group - Subset of intent to treat (ITT) Population who were wild type homozygous for chitotriosidase.	Week 53
Secondary	Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18)		Week 53

External Links

•   Shire product Information web site